Anavex Life Sciences Corp (AVXL)

[nidan7500]

IMO, This PR states that BIIB (others) have reached the end of the plaque rope and it has AVXL written all over it.

Biogen is looking to strengthen its AD and other neurodegenerative disorders pipeline. Notably, the company’s Alzheimer's disease (AD) pipeline comprises candidates with different mechanisms of action including anti-tau candidate (BIIB092/BMS-986168-with potential in AD as well as progressive supranuclear palsy (PSP)), anti-amyloid (aducanumab) candidates as well as a BACE inhibitor (elenbecestat) program.

However, the successful development of therapies for the treatment of Alzheimer’s disease is challenging and we note that several companies have failed in developing treatments for the same. In November 2016, Eli Lilly & Company's LLY anti-amyloid candidate — solanezumab failed to meet the primary endpoint in a late-stage AD study. Consequently, Lilly decided to drop the development of the candidate.
Meanwhile, Pfizer PFE shelved its late-stage Alzheimer’s candidate, bapineuzumab IV, after it failed two phase III studies. Pfizer was developing the candidate in collaboration with Johnson & Johnson JNJ and Elan Corporation.
The Alzheimer’s disease market represents a huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched.

So,if you have a lot of money and you are clueless about how to treat AD, what do you do?